Get the Stockscreener App
9.07
9.66%
-0.97
After Hours:
9.00
-0.07
-0.77%
Emergent Biosolutions Inc stock is traded at $9.07, with a volume of 1.17M.
It is down -9.66% in the last 24 hours and up +13.80% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$10.04
Open:
$9.97
24h Volume:
1.17M
Relative Volume:
1.05
Market Cap:
$483.89M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.6145
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
-0.87%
1M Performance:
+13.80%
6M Performance:
+112.91%
1Y Performance:
+7.34%
1-Day Range:
$9.06
$10.02
1-Week Range:
$8.85
$10.10
52-Week Range:
$4.02
$12.73
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
9.07 | 535.65M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Short interest data insights for Emergent BioSolutions Inc.July 2025 Spike Watch & Expert Approved Momentum Trade Ideas - newser.com
How strong is Emergent BioSolutions Inc. stock balance sheetJuly 2025 Update & Consistent Profit Alerts - newser.com
Emergent Biosolutions (NYSE:EBS) Given "Sell (D)" Rating at Weiss Ratings - MarketBeat
Is Emergent BioSolutions Inc. (ER4) stock dividend growth reliableQuarterly Trade Summary & Real-Time Sentiment Analysis - newser.com
Emergent BioSolutions Inc.'s (NYSE:EBS) Shares Bounce 31% But Its Business Still Trails The Industry - simplywall.st
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 - The Manila Times
Emergent BioSolutions Inc. Announces Conference Call for Third Quarter 2025 Financial Results - Quiver Quantitative
Emergent Biosolutions (NYSE:EBS) Stock Price Up 5.3%Still a Buy? - MarketBeat
Emergent Biosolutions (NYSE:EBS) Share Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Quantitative breakdown of Emergent BioSolutions Inc. recent moveTrade Ideas & Growth Focused Entry Reports - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is listed among top recommendationsWeekly Market Summary & Free Safe Entry Trade Signal Reports - newser.com
Is Emergent BioSolutions Inc. (ER4) stock a buy during volatile marketsJuly 2025 Opening Moves & Short-Term High Return Ideas - newser.com
Published on: 2025-10-05 04:23:16 - newser.com
Is Emergent BioSolutions Inc. stock a top pick in earnings season2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Relative strength of Emergent BioSolutions Inc. in sector analysisWeekly Trend Summary & Long-Term Capital Growth Ideas - newser.com
How to interpret RSI for Emergent BioSolutions Inc. stockPortfolio Update Report & Weekly Setup with ROI Potential - newser.com
Strategies to average down on Emergent BioSolutions Inc.Portfolio Value Report & AI Powered Market Trend Analysis - newser.com
Multi factor analysis applied to Emergent BioSolutions Inc.CEO Change & Entry Point Strategy Guides - newser.com
Is Emergent BioSolutions Inc. stock poised for growth2025 Stock Rankings & Consistent Profit Alerts - newser.com
Emergent BioSolutions Inc Stock Analysis and ForecastVolatility Index Analysis & Big Profit Small Budget - earlytimes.in
Is Emergent BioSolutions Inc ER4 a good long term investmentMarket Insider Reports & Affordable Investment Strategies - Early Times
Emergent Biosolutions Inc. $EBS Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Emergent BioSolutions Inc.'s (NYSE:EBS) large institutional owners must be happy as stock continues to impress, up 10% over the past week - Yahoo Finance
Emergent BioSolutions Inc. Reaffirms Commitment to Combat Opioid Crisis Through Awareness and Access to Naloxone Products - Quiver Quantitative
45% of Retail Workers Have Witnessed Naloxone Use: Emergent BioSolutions Tackles Workplace Opioid Crisis - Stock Titan
Emergent BioSolutions stock maintains Buy rating at H.C. Wainwright on $29M deal - Investing.com Canada
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Emergent Biosolutions Inc Stock (EBS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zoon Kathryn C | Director |
Aug 15 '25 |
Sale |
8.87 |
7,086 |
62,853 |
71,799 |
1.54%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):